Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Post-Transplant Cyclophosphamide (Post-Cy) for Haematological Malignancies: A Single Centre Experience
Only 30% of patients have fully HLA-matched donor. In patients with urgent need to transplant, the use of alternative haploidentical donor is the only chance for cure. The introduction of post-transplant Cyclophosphamide (PT-Cy) GvHD prophylaxis allowed to decrease GvHD rate.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Dmitry Motorin, Renat Badaev, Andrey Zaritskey Source Type: research
More News: Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants